Iterum Therapeutics (NASDAQ:ITRM) issued its earnings results on Tuesday. The company reported ($2.15) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.61) by ($0.54), Bloomberg Earnings reports. Iterum Therapeutics had a negative return on equity of 136.21% and a negative net margin of 11,956.64%.
ITRM stock traded down $0.02 during midday trading on Wednesday, reaching $2.41. 21,000 shares of the company’s stock traded hands, compared to its average volume of 14,348. The company has a 50-day simple moving average of $4.08 and a two-hundred day simple moving average of $6.09. Iterum Therapeutics has a 1-year low of $2.08 and a 1-year high of $9.30. The company has a market cap of $34.90 million, a price-to-earnings ratio of -0.34 and a beta of 1.82. The company has a quick ratio of 2.10, a current ratio of 2.10 and a debt-to-equity ratio of 0.44.
ITRM has been the subject of a number of recent research reports. Zacks Investment Research cut Iterum Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, October 25th. ValuEngine raised Iterum Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, October 4th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $17.00 price target on shares of Iterum Therapeutics in a report on Thursday, August 15th. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. Iterum Therapeutics has an average rating of “Buy” and a consensus price target of $15.75.
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. The company is developing sulopenem, a penem anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of adults in uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.
Recommended Story: Using other technical indicators with support levels
Receive News & Ratings for Iterum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iterum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.